PD-1 and PD-L1 Inhibitors Market Expands with 200+ Drugs in Development Across 180+ Companies
Feb 19, 2026
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.